Clinical Trial Update: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 1/2 study of Gedatolisib plus Talazoparib for advanced triple-negative breast cancer or BRCA1/2-mutated, HER2-negati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Gedatolisib (gedatolisib)
• Talazoparib (talazoparib)

Snippet

Sponsor: Kari Wisinski | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING